We proposed to determine, in a real-world clinical setting, the rate of TBI reactivation in psoriatic patients with previously or newly diagnosed LTBI, treated with risankizumab over a follow-up period of 52 weeks, comparing those who had undergone TB chemoprophylaxis with those who had not.
Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world study
Raimondo, A
Writing – Original Draft Preparation
;Lembo, SMethodology
2024-01-01
Abstract
We proposed to determine, in a real-world clinical setting, the rate of TBI reactivation in psoriatic patients with previously or newly diagnosed LTBI, treated with risankizumab over a follow-up period of 52 weeks, comparing those who had undergone TB chemoprophylaxis with those who had not.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
